A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women With Newly Diagnosed, Previously Untreated, Gynaecological Tumors.
Latest Information Update: 03 Jul 2023
Price :
$35 *
At a glance
- Drugs Pazopanib (Primary) ; Carboplatin; Paclitaxel
- Indications Gynaecological cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 12 May 2012 Planned number of patients changed from 46 to 52 as reported by European Clinical Trials Database record.
- 09 Oct 2009 Planned patient number (46) added as reported by ClinicalTrials.gov.
- 20 May 2009 Inclusion and exclusion criteria amended from NCT.